A vaccine to prevent cancer in people with Lynch Syndrome
Official title: Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome
Funded at University of Tx Md Anderson Can Ctr · NIH-11132877 · Data updated 2026-11-12
This project is developing a vaccine to help prevent various cancers in people who have Lynch Syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 22, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $831,115 |
| NIH project number | 5R01CA260761-04 |
| Project ID | NIH-11132877 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant for individuals diagnosed with Lynch Syndrome, particularly those at high risk for various cancers.
✕Less likely to help
Patients without Lynch Syndrome or other hereditary cancer syndromes would likely not benefit directly from this specific vaccine approach.
What this research studies
For people with Lynch Syndrome, a genetic condition increases their risk of many cancers, especially colorectal cancer. This research builds on findings that their immune system can recognize unique cancer markers. We are working to create a vaccine that targets these markers, called neoantigens, which are specific to Lynch Syndrome-related cancers. The goal is to combine this vaccine with an anti-inflammatory medicine, naproxen, to boost the body's natural defenses against cancer development. This work uses a special animal model to ensure the vaccine is safe and effective before it can be tested in people.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the risk of developing multiple cancers for individuals with Lynch Syndrome.
How similar studies have gone: Previous human trials have shown that certain medications can activate the immune system in Lynch Syndrome patients, and a detailed catalog of cancer markers has been identified, suggesting a strong foundation for this vaccine approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
- Study coordinator: Vilar Sanchez, Eduardo
Related research
Other NIH-funded projects on the same topics.
-
Immune clues to prevent cancer in Lynch Syndrome
A study exploring how immune signals and shared neoantigens in Lynch Syndrome could help prevent cancer by training the immune system to recognize and fight premalignant lesions.
-
Personalized, Noninvasive Surveillance for Lynch Syndrome Colorectal Cancer
This project tests a noninvasive fecal test (FIT) alongside colonoscopy to tailor colorectal cancer surveillance for people with Lynch syndrome.
-
Behavioral tool to boost pre-test genetic counseling for Lynch syndrome families
A risk-based program helps families at risk for Lynch syndrome get pre-test counseling more often, so they can learn about genetic testing and cancer prevention.
-
Cancer vaccines for Lynch syndrome in a non-human primate model
A researcher is testing a vaccine approach to help prevent Lynch syndrome–related cancers by training the immune system to recognize cancer-causing changes in the colon using a primate model.
-
Neoantigen vaccine for Lynch syndrome immune interception
A study to test a vaccine that teaches the immune system to recognize cancer-causing mutations in people with Lynch syndrome.
-
Personalized colorectal cancer screening for people with Lynch syndrome
This project aims to find the best colonoscopy schedule for people with Lynch syndrome based on their specific gene.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.